secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001437749-25-037209
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports MIRACLE AML trial enrollment at 78% of 45-subject interim target
--------------------------------------------------------------------------------

- Enrollment increased to 78% of target for first interim unblinding (up from 60% in Nov).
- First unblinding will involve 45 subjects; treatment completion expected Q1 2026.
- Consented subjects across seven countries; recruitment ongoing beyond the 78% mark.
- Part A of trial (90 subjects) expected to complete enrollment in H1 2026.
- Blinded response activity tracking within expected range per CEO commentary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925037209/0001437749-25-037209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925037209/mbrx20251208_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-037209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer